GLP1R and heart disorder: The association between GLP-1 RA use and the primary composite endpoint was generally consistent across several subgroups in the PS-matched cohort, except for an associated lower risk in patients without ischaemic heart disease but not in those with ischaemic heart disease (P-value for interaction: 0.002), and in patients with preserved renal function vs. those with impaired renal function (P-value for interaction: 0.037) (Figure 3, see Supplementary material online, Table S4–S7 and Figure S6).